Search
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: ROPINIROLO EG, ROPINIROLO EG STADADabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Categories: Heterocyclic Compounds, 2-RingProducts: PRADAXA 110 MG SERT KAPSUL, 10 ADET, PRADAXA 75 MG SERT KAPSUL, 10 ADETQuinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnIt is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. … Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.
Synonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideCategories: Heterocyclic Compounds, 2-RingPanitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalThis drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]
Products: Vectibix Concentrate for Solution for Infusion 100 mg/vial, VECTIBIX® 20 MG/ MLSodium aurothiomalate
go.drugbank.com/drugs/DB09276ApprovedWithdrawnGold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. … It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Products: MIOCRIN 50 MG, MYOCRISIN INJECTION 20 MG (4% W/V)Misoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] … [L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the
Mixtures: ARTHROTEC 75 MG 10 TABLET, DIFEMIS 50 MG/0.2 MG TABLET, 20 ADETCategories: Prostaglandin E1 Analog, Prostaglandins E, SyntheticAlteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalAlteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. … [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).
Synonyms: t-PA, rt-PAMixtures: Activase RT-PA, Lysatec RT - PaLacidipine
go.drugbank.com/drugs/DB09236ApprovedIt is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: LACIDIPINA EG, LACIPIL 4 MG FILM KAPLI TABLET, 28 ADETLevosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan is under investigation in clinical trial NCT00527059 (Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure). … It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Categories: Compounds used in a research, industrial, or household settingProducts: LEVOSIMENDAN EG, SIMDAX 2.5 MG/ML KONSANTRE INF.COZ.5 ML X FLAKON, 1 ADETSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: XADAGO 100 MG TABLETASRECUBIERTAS CON PELÍCULA, Equfina Film coated Tablets 50 mg